Heart transplantation
2019 ◽
pp. 165-182
Keyword(s):
Heart transplantation remains the treatment of choice for end-stage heart failure refractory to conventional treatment. Long-term outcome is excellent, and median survival currently exceeds 13 years. The main causes of death late after transplantation are cardiac allograft vasculopathy and cancer. Medical therapy after transplantation is complex, including immunosuppressive therapy to reduce the risk of graft rejection and prophylaxis against viral and protozoal infections, as well as adjunctive therapy to treat common comorbidities, for instance hypertension. Pharmacological therapy of comorbid conditions requires specific consideration to clinically important interactions with immunosuppressive drugs.
2019 ◽
pp. 165-182
2016 ◽
Vol 118
(3)
◽
pp. 383-388
◽
Keyword(s):
2021 ◽
Keyword(s):
2008 ◽
Vol 7
◽
pp. 199-199
2007 ◽
Vol 15
(5)
◽
pp. 446-448
◽
2021 ◽
Keyword(s):
Keyword(s):
2019 ◽
Vol 38
(4)
◽
pp. S287-S288
2021 ◽
Vol 10
(Supplement_1)
◽
2005 ◽
Vol 53
(1)
◽
pp. S121.5-S122